BRCA1 mutations predispose to early-onset breast cancer. We previously reported an association between absence of the common
IGF1 19 CA-repeat allele (
IGF1-19/-19) and being a
BRCA1 mutation carrier in young women from breast cancer high-risk families. Others have reported a four-fold risk of premenopausal
breast cancer in women with a family history and the
IGF1-19/-19 genotype. The aim of this study was to investigate whether the
IGF1-19/-19 genotype was associated with being a
BRCA1 mutation carrier among women from
BRCA1 families. DNA was available from 268 women with known
BRCA1 status from the South Swedish Health Care Region.
IGF1 genotyping was successfully performed with fragment analysis in 211 women from 96 families. The
IGF1-19/-19 genotype was significantly more common among
BRCA1 mutation carriers (14.2%) than among non-carriers (4.8%), OR 3.3 (95%CI 1.11–9.78,
P = 0.03) adjusted for family clustering. We confirmed our previous finding of an association between the
IGF1-19/-19 genotype and
BRCA1 mutation status. Since the
IGF1-19/-19 genotype in combination with OC use or multiparity confers an increased risk for early onset breast cancer in high-risk
women and in women from the general population, future studies are needed to elucidate the importance of the
IGF1-19/-19 genotype concerning the variability in breast cancer risk among
BRCA1 mutation carriers.
Keywords
BRCA1
- Breast cancer - Genotype -
IGF1
- Oral contraceptive - Parity
Maria Henningson and Erika Bågeman contributed equally.